Takeda Launches New Subsidiary in Peru - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda Launches New Subsidiary in Peru



Takeda Pharmaceuticals International GmbH has expanded its presence in Latin America with the addition of a wholly-owned subsidiary in Peru. Takeda Peru will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Takeda has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia, Ecuador and now Peru. According to IMS Market Prognosis, pharmaceutical sales in those countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017.

It is estimated that Peru’s GDP totaled $200 billion in 2012 while pharmaceutical sales amounted to $1.5 billion and are expected to continue to grow by 8% during 2013*.

Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the organization from Takeda Colombia, where he headed the Takeda Sales and Marketing organization following the acquisition of Farmacol Laboratories.

Source: Takeda Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here